Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Hyperthermia × spartalizumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 6 Neoplasms 6 Melanoma 5 Neoplasm Metastasis 4 Uterine Cervical Neoplasms 3 Lung Neoplasms 3 Head and Neck Neoplasms 3 Carcinoma, Non-Small-Cell Lung 3 Triple Negative Breast Neoplasms 2 Squamous Cell Carcinoma of Head and Neck 2 Solid Tumor 2 Liver Neoplasms 2 Glioblastoma 2 Endometrial Neoplasms 2 Carcinoma, Hepatocellular 2 Breast Neoplasms 2 Thyroid Carcinoma, Anaplastic 1 Stomach Neoplasms 1 Solid Tumor, Adult 1 Sarcoma 1 Salivary Gland Neoplasms 1 Recurrence 1 Pelvic Neoplasms 1 Ovarian Neoplasms 1 Nasopharyngeal Neoplasms 1 Nasopharyngeal Carcinoma 1 Mesothelioma, Malignant 1 Lymphoma 1 Lung Diseases 1 Locally Advanced or Metastatic Solid Tumors 1

Interventions

tislelizumab 1 spartalizumab 1 Immune Checkpoint Inhibitors 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06022692 2023-09-05

HEAIS001

Zhejiang Hospital

Phase 1/2 Completed

Gastrointestinal

Hyperthermia, Digestive System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡